JCIC Asset Management Inc. Has $3.20 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

JCIC Asset Management Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO) by 1.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,207 shares of the company’s stock after buying an additional 665 shares during the quarter. Novo Nordisk A/S makes up about 1.3% of JCIC Asset Management Inc.’s holdings, making the stock its 26th biggest position. JCIC Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $3,201,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Meeder Advisory Services Inc. bought a new position in Novo Nordisk A/S during the second quarter worth about $884,000. GHP Investment Advisors Inc. increased its holdings in shares of Novo Nordisk A/S by 2.9% in the second quarter. GHP Investment Advisors Inc. now owns 4,694 shares of the company’s stock worth $670,000 after acquiring an additional 134 shares in the last quarter. J.W. Cole Advisors Inc. raised its position in shares of Novo Nordisk A/S by 57.7% during the second quarter. J.W. Cole Advisors Inc. now owns 14,553 shares of the company’s stock worth $2,077,000 after purchasing an additional 5,322 shares during the period. Diversify Wealth Management LLC bought a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $4,940,000. Finally, Pinion Investment Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $353,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Down 2.2 %

NVO traded down $1.93 on Monday, hitting $84.33. 5,607,502 shares of the company were exchanged, compared to its average volume of 7,144,377. The stock’s fifty day moving average is $100.35 and its 200-day moving average is $119.04. Novo Nordisk A/S has a 12 month low of $81.50 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market cap of $378.43 billion, a PE ratio of 27.29, a PEG ratio of 1.37 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.